-
公开(公告)号：US09550826B2
公开(公告)日：2017-01-24
申请号：US15198696
申请日：2016-06-30
Applicant: AbbVie Inc.
Inventor： Boris Labkovsky , Tariq Ghayur , Georgeen Gaza-Bulseco , Pratibha Mishra , Subramanya Hegde , Sudha Krishnan
CPC classification number: C07K16/241 , A61K2039/505 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/30 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/77 , Y02A50/386
Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
Abstract translation: 提供具有减少的抗药物免疫应答（ADA）的具有Fc结构域的结合蛋白的糖工程化群体。 还提供了使用这种组合物治疗疾病的方法，以及制备这种组合物的方法和宿主。
-
公开(公告)号：US09447183B2
公开(公告)日：2016-09-20
申请号：US14107988
申请日：2013-12-16
Applicant: AbbVie, Inc.
Inventor： Chengbin Wu , Dominic J. Ambrosi , Chung-ming Hsieh , Tariq Ghayur
IPC: C12P21/08 , A61K38/00 , C07K14/545 , C07K16/24 , A61K47/48 , A61K45/06 , G01N33/68 , A61K39/395 , A61K9/00
CPC classification number: C07K16/245 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/007 , A61K9/0085 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K47/6879 , C07K14/545 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545 , G01N2800/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/412 , Y02A50/463 , Y02A50/478 , Y02A50/481
Abstract: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.
-
公开(公告)号：US09441038B2
公开(公告)日：2016-09-13
申请号：US14109606
申请日：2013-12-17
Applicant: AbbVie, Inc.
Inventor： Chengbin Wu , Dominic J. Ambrosi , Chung-ming Hsieh , Tariq Ghayur
IPC: A61K38/00 , C07K14/545 , C07K16/24 , A61K39/395 , A61K47/48 , A61K45/06 , G01N33/68 , A61K9/00
CPC classification number: C07K16/245 , A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/007 , A61K9/0085 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K47/6879 , C07K14/545 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545 , G01N2800/00 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/412 , Y02A50/463 , Y02A50/478 , Y02A50/481
Abstract: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.
-
14.发明申请公开(公告)号：US20150344590A1
公开(公告)日：2015-12-03
申请号：US14713251
申请日：2015-05-15
Applicant: ABBVIE INC.
Inventor： Tariq Ghayur , JiJie Gu , Maria Harris , Carrie Goodreau , Sonal Saluja
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K47/6879 , C07K16/244 , C07K16/245 , C07K2317/31 , C07K2317/626 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , G01N33/6869 , G01N2333/54 , G01N2333/545
Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 结合IL-1和bgr的工程化多价和多特异性结合蛋白 和/或IL-17，以及在预防，诊断和/或治疗疾病中的制备和用途的方法。
-
公开(公告)号：US20140271457A1
公开(公告)日：2014-09-18
申请号：US14211596
申请日：2014-03-14
Applicant: ABBVIE INC.
Inventor： Tariq Ghayur , Carrie Goodreau
CPC classification number: G01N33/6863 , A61K45/06 , A61K47/6879 , A61K51/109 , C07K16/22 , C07K16/241 , C07K16/244 , C07K16/26 , C07K2317/31 , C07K2317/35 , C07K2317/56 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , G01N33/6869 , Y02A50/58
Abstract: Engineered multivalent and multispecific binding proteins that bind TNFα and IL-13, TNFα and PGE2, or TNFα and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 提供结合TNFα和IL-13，TNFα和PGE2或TNFα和NGF的工程化多价和多特异性结合蛋白，以及制备和用于预防，诊断和/或治疗疾病的方法。
-
Patent Agency Ranking
公开(公告)号：US20140155579A1
公开(公告)日：2014-06-05
申请号：US13900841
申请日：2013-05-23
Applicant: AbbVie Inc.
Inventor： Albert Collinson , George Avgerinos , Richard Dixon , Tariq Ghayur , Zehra Kaymakcalan
IPC: C07K16/24
CPC classification number: C07K16/245 , A61K47/6845 , A61K2039/505 , C07K14/545 , C07K16/46 , C07K16/468 , C07K2317/10 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/76 , G01N33/6869
Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental.
Abstract translation: 提供了对两种不同但结构相关抗原具有双重特异性的抗体。 抗体可以是例如完全是人抗体，重组抗体或单克隆抗体。 优选的抗体对IL-1α和IL-1＆bgr具有双重特异性; 并中和IL-1α和IL-1和bgr; 体外和体内活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测两种不同但结构相关的抗原（例如，IL-1α和IL-和bgr），并且用于抑制抗原的活性，例如在患有 其中IL-1α和/或IL-1和bgr的病症 活动是有害的。
-
17.发明申请公开(公告)号：US20190233510A1
公开(公告)日：2019-08-01
申请号：US16055659
申请日：2018-08-06
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Mario Mezler , Achim Moeller , Reinhold Mueller , Bernhard K. Mueller , Tariq Ghayur , Eve H. Barlow , Martin Schmidt , Axel Meyer , Nicole Teusch
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/28 , A61K39/3955 , A61K2039/505 , C07H21/00 , C07K16/2863 , C07K2317/14 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
-
公开(公告)号：US20180194861A1
公开(公告)日：2018-07-12
申请号：US15742331
申请日：2016-07-08
Applicant: AbbVie Inc.
Inventor： Feng Dong , Jijie Gu , Tariq Ghayur
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/31 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/64 , C07K2319/00 , C07K2319/30
Abstract: Engineered binding proteins comprising a modified constant region, such as an IgG constant region modified to contain a CH2 domain from an IgM, a CH2 domain from an IgE, or a variant thereof, are disclosed. The binding proteins can be multispecific, including bi-, tri-, and tetra-specific constructs. Also disclosed are uses of the binding proteins in the diagnosis, prevention, and/or treatment of disease.
-
公开(公告)号：US09493560B2
公开(公告)日：2016-11-15
申请号：US14135107
申请日：2013-12-19
Applicant: AbbVie, Inc.
Inventor： Tariq Ghayur , Junjian Liu , Peter C. Isakson
IPC: A61K39/395 , A61K39/40 , C07K16/24 , C07K16/46 , G01N33/53 , G01N33/68 , A61K45/06 , A61K47/48 , A61K49/00 , A61K51/10 , G01N33/569 , C07K16/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K49/00 , A61K51/1021 , C07K16/241 , C07K16/245 , C07K16/468 , C07K2317/35 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/53 , G01N33/56966 , G01N33/6857 , G01N33/6869 , G01N2333/54 , G01N2333/545 , G01N2800/24 , G01N2800/7028
Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.
-
公开(公告)号：US20160319026A1
公开(公告)日：2016-11-03
申请号：US15091468
申请日：2016-04-05
Applicant: AbbVie Inc.
Inventor： Tariq Ghayur , Junjian Liu , Gillian A. Kingsbury , Edward B. Reilly , Susan E. Morgan-Lappe , Jijie Gu
IPC: C07K16/28 , G01N33/74 , A61K39/395 , A61K47/48 , A61K45/06
CPC classification number: C07K16/2863 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6879 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K16/2809 , C07K16/40 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/74 , G01N2333/71 , Y02A50/386 , Y02A50/41 , Y02A50/412
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
-
-
-
-
-
-
-
-
-
Search Results
57
records
(took 0.049 seconds)
